Recall
FDAHealthJune 8, 2026

Siemens Healthcare Diagnostics, Inc. — Atellica CH Enzymatic Hemoglobin A1c (A1c_E). Material Number: 11097536.

⚠️ The potential for intermittent well-to-well bias on the A1c_E assay on the Atellica CH and Atellica CI analyzer which could cause falsely depressed or falsely elevated HbA1c patient results.

Is this relevant to me?

Geography
Nationwide
Source agency
FDA
Category
Health
Published
June 8, 2026

Worldwide distribution - US Nationwide and the countries of Argentina, Australia, Austria, Bahamas, Bangladesh, Bolivia, Brazil, Bulgaria, Burkina¿Faso, Canada, Chile, China, Colombia, Croatia, Cura¿ao,¿St¿Eus, Czech¿Republic, Democratic Republic Congo, Denmark, Ecuador, Egypt, El Salvador, Estonia, Finland, France, Georgia, Germany, Greece, Hong Kong, India, Indonesia, Israel, Italy, Japan, Jordan, Kenya, Kuwait, Latvia, Lebanon, Lithuania, Macedonia, Malaysia, Mexico, Netherlands, New Zealand, Norway, Oman, Pakistan, Paraguay, Poland, Portugal, Qatar, Republic of Korea, Romania, Saudi¿Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, Spain, Switzerland, Thailand, Turkey, Turkmenistan, U.A.E., Uganda, United¿Kingdom, Uruguay, Vatican City, Vietnam.

What's affected?

Product
Atellica CH Enzymatic Hemoglobin A1c (A1c_E). Material Number: 11097536.
Lot code
s

Additional details

Material Number: 11097536. UDI-DI: 00630414220505. All Lot Numbers.

What should I do?

Recommended action

Class II recall. Voluntary: Firm initiated Quantity affected: 24,077 units.

View original FDA notice →

Get Health recall alerts

Delivered to your inbox. Free. No account required.